SCHEMBL6357776

SCHEMBL6357776

Oc1cccc(COc2ccccc2OCc2cccc(O)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 4/20 0.53
ENPP2 Q13822 2/20 0.52
MAPK1 P28482 2/20 0.52
MAPT P10636 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
NFKB1 P19838 2/20 0.49
CALM1 P0DP23 1/20 0.49
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49
MITF O75030 1/20 0.49
TP53 P04637 1/20 0.49
HPGD P15428 1/20 0.49
XBP1 P17861 1/20 0.49
RAB9A P51151 1/20 0.49
NFKB2 Q00653 1/20 0.49
KMT2A Q03164 1/20 0.49
RELA Q04206 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
DRD2 P14416 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12505430 0.87 APP (0.56) MRGPRX4ENPP2MAPK1MAPTTDP1
SCHEMBL6553017 0.87 HPGD (0.66) MRGPRX4ENPP2MAPTTDP1NFKB1
SCHEMBL15613732 0.83 MRGPRX4 (0.68) MRGPRX4ENPP2MAPK1MAPTTDP1
SCHEMBL13192152 0.83 ATM (0.52) MRGPRX4MAPK1L3MBTL1NPC1RAB9A
SCHEMBL21945455 0.82 MRGPRX4 (0.67) MRGPRX4ENPP2MAPTTDP1NFKB1
SCHEMBL12505427 0.82 PARP1 (0.64) MRGPRX4MEN1NPC1RAB9AKMT2A
SCHEMBL13192629 0.82 LMNA (0.62) MAPTL3MBTL1MEN1RAB9AKMT2A
SCHEMBL6359071 0.81 MRGPRX4 (0.51) MRGPRX4ENPP2NPC1DRD2DRD1
SCHEMBL10562035 0.79 LTA4H (0.69) ENPP2MAPK1MAPTNFKB1MEN1
SCHEMBL13192251 0.78 BRD4 (0.76) MAPTTDP1L3MBTL1MEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210317068-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION OHIO UNIVERSITY 2021-10-14 US disclosed
US-11072576-B2 Compositions and methods for glucose transport inhibition OHIO UNIVERSITY (US) 2021-07-27 US disclosed
US-20190345094-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION OHIO UNIVERSITY 2019-11-14 US disclosed
US-10385005-B2 Compositions and methods for glucose transport inhibition OHIO UNIVERSITY (US) 2019-08-20 US disclosed
US-10000443-B2 Compositions and methods for glucose transport inhibition OHIO UNIVERSITY (US) 2018-06-19 US disclosed
US-10000443-B2 Compositions and methods for glucose transport inhibition OHIO UNIVERSITY (US) 2018-06-19 US disclosed
US-20160137585-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION OHIO UNIVERSITY (US) 2016-05-19 US disclosed
US-9181162-B2 Compositions and methods for glucose transport inhibition OHIO UNIVERSITY (US) 2015-11-10 US disclosed
US-20120121536-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION OHIO UNIVERSITY (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317068-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION SLC2A1, SLC2A4, SLC2A3 MRGPRX4 3273/4885ENPP2 1432/4885MAPK1 1094/4885
US-20160137585-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION SLC2A1, SLC2A4, SLC2A3 MRGPRX4 3273/4885ENPP2 1432/4885MAPK1 1094/4885
US-10385005-B2 Compositions and methods for glucose transport inhibition SLC2A1, SLC2A4, SLC2A3 MRGPRX4 3273/4885ENPP2 1432/4885MAPK1 1094/4885
US-20190345094-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION SLC2A1, SLC2A4, SLC2A3 MRGPRX4 3273/4885ENPP2 1432/4885MAPK1 1094/4885
US-11072576-B2 Compositions and methods for glucose transport inhibition SLC2A1, SLC2A4, SLC2A3 MRGPRX4 3273/4885ENPP2 1432/4885MAPK1 1094/4885
US-20120121536-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION SLC2A1, SLC2A4, SLC2A3 MRGPRX4 3273/4885ENPP2 1432/4885MAPK1 1094/4885
US-10000443-B2 Compositions and methods for glucose transport inhibition SLC2A1, SLC2A4, SLC2A3 MRGPRX4 3273/4885ENPP2 1432/4885MAPK1 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.